Glenmark Pharma unveils Teneligliptin plus Dapagliflozin FDC for type 2 diabetes
Glenmark’s Zita D is priced at around Rs 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and Rs 15 per tablet for FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg, per day.
Mumbai: Glenmark Pharmaceuticals Limited, a global pharmaceutical company, has announced the launch of Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed-dose combination (FDC) for the treatment of adult patients with type 2 diabetes, especially the ones with comorbidities.
Marketed under the brand name Zita D; it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg) and must be taken once daily under prescription to improve glycemic control & prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities.
According to IQVIATM sales data for the 12‐month period ending Sept. 2022, the market for oral anti‐diabetic drugs in India is estimated to be INR 11,796 cr. with an annual growth of 7% against the corresponding period last year (MAT Sept. 2021). As per the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045 Out of these, 77% of patients have uncontrolled diabetes. Moreover, about eight out of ten patients with diabetes also have one or more comorbidity in India.
Read also: Glenmark Specialty, Hikma Pharma launch seasonal allergic rhinitis nasal spray RYALTRIS in US
